These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26363097)

  • 1. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
    Shuang T; Wang M; Shi C; Zhou Y; Wang D
    FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
    Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
    BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
    Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
    Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
    Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2.
    Xia B; Lin M; Dong W; Chen H; Li B; Zhang X; Hou Y; Lou G
    J Biochem Mol Toxicol; 2018 Aug; 32(8):e22168. PubMed ID: 30004169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera.
    Liu N; Zhou C; Zhao J; Chen Y
    Cancer Invest; 2012 Oct; 30(8):577-82. PubMed ID: 22812695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
    Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells.
    Miyamoto M; Sawada K; Nakamura K; Yoshimura A; Ishida K; Kobayashi M; Shimizu A; Yamamoto M; Kodama M; Hashimoto K; Kimura T
    Sci Rep; 2020 Oct; 10(1):16755. PubMed ID: 33028939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
    Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-125b Suppresses Ovarian Cancer Progression via Suppression of the Epithelial-Mesenchymal Transition Pathway by Targeting the SET Protein.
    Ying X; Wei K; Lin Z; Cui Y; Ding J; Chen Y; Xu B
    Cell Physiol Biochem; 2016; 39(2):501-10. PubMed ID: 27383536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
    Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
    Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
    Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
    Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin and epithelial ovarian cancer therapeutics.
    Patel S; Kumar L; Singh N
    Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.